UnitedHealth Group Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>UnitedHealth Group Inc. has filed its comprehensive 2023 annual report on Form 10-K.</b>

AI Summary

UNITEDHEALTH GROUP INC (UNH) filed a Annual Report (10-K) with the SEC on February 28, 2024. UnitedHealth Group Inc. reported its 2023 fiscal year results on Form 10-K, filed on February 28, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located in Minneapolis, MN. UnitedHealth Group Inc. was formerly known as United HealthCare Corp. The filing is a 10-K report, indicating a comprehensive annual disclosure.

Why It Matters

For investors and stakeholders tracking UNITEDHEALTH GROUP INC, this filing contains several important signals. This 10-K filing provides a detailed overview of UnitedHealth Group's financial performance, operational strategies, and risk factors for the fiscal year 2023, crucial for investors assessing the company's health and future prospects. As a major player in the healthcare industry, UnitedHealth Group's annual report offers insights into industry trends, regulatory impacts, and competitive dynamics affecting the broader healthcare sector.

Risk Assessment

Risk Level: medium — UNITEDHEALTH GROUP INC shows moderate risk based on this filing. The company operates in a highly regulated industry, facing potential changes in healthcare policy and reimbursement rates that could impact financial performance.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand UnitedHealth Group's performance and outlook for 2024.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-02-28 — Filing Date (Filed as of date)
• 132 — Public Document Count (Number of documents in the filing)
• 6324 — SIC Code (Standard Industrial Classification)

Key Players & Entities

• UNITEDHEALTH GROUP INC (company) — Filer name
• 0000731766 (company) — Central Index Key
• MINNEAPOLIS (company) — Business address city
• DE (company) — State of incorporation
• UNITED HEALTHCARE CORP (company) — Former company name
• 2023-12-31 (date) — Conformed period of report
• 2024-02-28 (date) — Filed as of date

FAQ

Industry Context

UnitedHealth Group operates within the expansive healthcare industry, encompassing health insurance and health services.

Regulatory Implications

The healthcare sector is subject to significant government regulation, including Medicare and Medicaid programs, and evolving healthcare policies.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management discussion.
2. Analyze the risk factors section for potential challenges and uncertainties.
3. Compare 2023 performance metrics against prior years and industry benchmarks.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-02-28: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This filing is the 2023 annual report on Form 10-K, providing updated financial and operational information compared to previous filings.

Key Financial Figures

• $480.64 — ased on the last reported sale price of $480.64 per share on June 30, 2023 as reported
• $22 billion — 4 million consumer accounts with nearly $22 billion in assets under management as of Decemb
• $32.1 b — of December 31, 2023 was approximately $32.1 billion, of which $18.7 billion is expect
• $18.7 billion — s approximately $32.1 billion, of which $18.7 billion is expected to be realized within the n
• $11.9 billion — months. The aggregate backlog includes $11.9 billion related to affiliated agreements. Optum
• $30.0 b — te backlog as of December 31, 2022, was $30.0 billion, including $10.7 billion related
• $10.7 billion — 31, 2022, was $30.0 billion, including $10.7 billion related to affiliated agreements. Optu
• $159 billion — se disorders. In 2023, Optum Rx managed $159 billion in pharmaceutical spending, including $
• $63 billion — n in pharmaceutical spending, including $63 billion in specialty pharmaceutical spending.

Filing Documents

• unh-20231231.htm (10-K) — 2640KB
• unhex10212312023.htm (EX-10.2) — 132KB
• unhex10312312023.htm (EX-10.3) — 117KB
• unhex10412312023.htm (EX-10.4) — 134KB
• unhex10512312023.htm (EX-10.5) — 117KB
• unhex10612312023.htm (EX-10.6) — 118KB
• unhex10712312023.htm (EX-10.7) — 118KB
• unhex10812312023.htm (EX-10.8) — 117KB
• unhex10912312023.htm (EX-10.9) — 117KB
• unhex101012312023.htm (EX-10.10) — 115KB
• unhex103012312023.htm (EX-10.30) — 51KB
• unhex103112312023.htm (EX-10.31) — 285KB
• unhex21112312023.htm (EX-21.1) — 1835KB
• unhex23112312023.htm (EX-23.1) — 3KB
• unhex24112312023.htm (EX-24.1) — 16KB
• unhex31112312023.htm (EX-31.1) — 19KB
• unhex32112312023.htm (EX-32.1) — 9KB
• unhex97112312023.htm (EX-97.1) — 21KB
• uhglogoclean.jpg (GRAPHIC) — 8KB
• uhglogoclean4.jpg (GRAPHIC) — 8KB
• uhglogoclean6.jpg (GRAPHIC) — 8KB
• uhglogoclean7.jpg (GRAPHIC) — 8KB
• uhglogocleana.jpg (GRAPHIC) — 8KB
• uhglogocleanb.jpg (GRAPHIC) — 16KB
• uhglogocleanc.jpg (GRAPHIC) — 8KB
• unh-20231231_g1.jpg (GRAPHIC) — 8KB
• unh-20231231_g2.jpg (GRAPHIC) — 266KB
• 0000731766-24-000081.txt (&nbsp;) — 19260KB
• unh-20231231.xsd (EX-101.SCH) — 75KB
• unh-20231231_cal.xml (EX-101.CAL) — 107KB
• unh-20231231_def.xml (EX-101.DEF) — 692KB
• unh-20231231_lab.xml (EX-101.LAB) — 1131KB
• unh-20231231_pre.xml (EX-101.PRE) — 840KB
• unh-20231231_htm.xml (XML) — 2685KB

Risk Factors

Item 1A. Risk Factors 10

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 20

Cybersecurity

Item 1C. Cybersecurity 21

Properties

Item 2. Properties 22

Legal Proceedings

Item 3. Legal Proceedings 22

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 22 Part II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 22

Reserved

Item 6. Reserved 23

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 24

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 33

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 35

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 66

Controls and Procedures

Item 9A. Controls and Procedures 66

Other Information

Item 9B. Other Information 69

Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 69 Part III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 69

Executive Compensation

Item 11. Executive Compensation 69

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 70

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 70

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 70 Part IV

Exhibit and Financial Statement Schedules

Item 15. Exhibit and Financial Statement Schedules 71

Form 10-K Summary

Item 16. Form 10-K Summary 79

Signatures

Signatures 80 PART I

BUSINESS

ITEM 1. BUSINESS OUR BUSINESSES Overview The terms "we," "our," "us," "its," "UnitedHealth Group," or the "Company" used in this report refer to UnitedHealth Group Incorporated and its subsidiaries. UnitedHealth Group Incorporated is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve. The ability to analyze complex data and apply deep health care expertise and insights allows us to serve patients, consumers, care providers, businesses, communities and governments with more innovative products and complete, end-to-end offerings for many of the biggest challenges facing health care today. Optum seeks to create a higher-performing, value-oriented and more connected approach to health care. Bringing together clinical expertise, technology and data to make care simpler, more effective and more affordable, we seek to advance whole-person health, creating a seamless consumer experience and supporting clinicians with insights to deliver personalized, evidence-based care. Optum serves the broad health care marketplace, including patients and consumers, payers, care providers, employers, governments and life sciences companies, through its Optum Health, Optum Insight and Optum Rx businesses. These businesses improve overall health system performance by optimizing health care quality and delivery, reducing costs and improving patient, consumer and provider experience, leveraging distinctive capabilities in data and analytics, pharmacy care services, health care operations, population health and health financial services. UnitedHealthcare offers a full range of health benefits designed to simplify the health

View Full Filing

View this 10-K filing on SEC EDGAR